Aclarion, Inc. has partnered with the Institute of Neuro Innovation in Los Angeles to expand the use of its Nociscan platform, which helps identify painful discs in chronic low back pain patients. This collaboration aims to generate real-world evidence by comparing Nociscan's chemical biomarker data with bone metabolic data from SPECT-CT scans, enhancing diagnostic precision. Nociscan's noninvasive technology supports better treatment decisions and has shown a 97% surgical success rate when used to guide treatment. This partnership supports Aclarion's growth strategy and could improve adoption by healthcare providers and payers.
Olson Wealth Group, led by Sharon Olson, has enhanced its exit and liquidity planning services by integrating business strategy, tax planning, estate architecture, and family office services into one coordinated approach. This expansion aims to help ...
SpaceX, led by Elon Musk, is weeks away from going public with an IPO targeting a $2 trillion market capitalization. Prediction market bettors on Polymarket assign a 75% chance that SpaceX's valuation will exceed $2 trillion after the IPO, with high ...
Zhihu Inc. announced the appointment of Qu Chen as a new non-executive director, effective June 3, 2026. He replaces Bing Yu, who resigned to focus on other business commitments. Qu Chen brings over 13 years of experience in strategic investment and ...
Chinese AI startup DeepSeek is preparing to raise about $7.4 billion in its first external funding round, potentially valuing the company between $51 billion and $59 billion. Major investors expected to participate include Tencent, which may invest a...
Levicept Ltd revealed Phase II clinical trial data for LEVI-04, a novel osteoarthritis treatment, at the EULAR 2026 conference. The data suggest LEVI-04 not only relieves pain but may also modify the disease by reducing bone marrow lesions linked to ...
